{
    "key_points": [
        "The FDA has issued an emergency use authorization (EUA) for AstraZeneca's Evusheld for pre-exposure prevention of COVID-19 in certain individuals.",
        "Evusheld is authorized for use in adults and pediatric individuals 12 years of age and older weighing at least 40 kilograms (~88 pounds).",
        "The authorization specifies that Evusheld is for individuals not currently infected with SARS-CoV-2, not recently exposed to it, and either immunocompromised or having a history of severe adverse reactions to COVID-19 vaccines.",
        "Patrizia Cavazzoni, M.D., highlighted the importance of vaccines but noted the need for prevention alternatives in certain individuals.",
        "Evusheld includes a combination of two monoclonal antibodies, tixagevimab and cilgavimab, and is designed for a six-month efficacy period.",
        "The treatment is administered via two consecutive intramuscular injections but is not a substitute for vaccination.",
        "FDA stresses that vaccination remains recommended for those eligible, emphasizing the authorization of various COVID-19 vaccines.",
        "Monoclonal antibodies in Evusheld aim to block the virus by targeting the spike protein.",
        "The primary data for the EUA comes from the PROVENT clinical trial, showing a 77% reduced risk of developing COVID-19 for Evusheld recipients over those receiving a placebo.",
        "Side effects of Evusheld include hypersensitivity reactions, bleeding at the injection site, headache, fatigue, cough, and in rare cases, serious cardiac adverse events."
    ],
    "spokespersons": [
        "Patrizia Cavazzoni, M.D. (Director of the FDA's Center for Drug Evaluation and Research)"
    ],
    "article_type": "press release",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}